 |
| Adynxx's Julien Mamet and Rick Orr. |
A team that built and sold three Bay Area drug companies over the past decade is looking for a fourth. But the latest venture, called Adynxx Inc., could be a big pain. The young San Francisco company is entering its first human trial of a treatment to prevent post-surgical pain and, ultimately, chronic pain.
No comments:
Post a Comment